About Us

Solutions for Precision Medicine:

  • Microfluidics
  • Biomarkers
  • Point-of-care and companion diagnostics
  • Drug discovery
FlowCell was founded in 2019 to develop enabling tools for life sciences. The founder Max Narovlyansky has received his Ph.D. in microfluidics with one of the field experts, Prof. Whitesides at Harvard University. He has over 15 years of experience in drug development and diagnostics. FlowCell’s vision is to provide tools for precision medicine by eliminating the artificial boundary between drug development and diagnostics.

One of the main tools for precision medicine is companion diagnostics (CDx) -- a biological assay that matches patient response to the treatment options. It predicts if the patient will have a favorable or unfavorable reaction to a specific treatment by using the biomarkers. CDx assays are beneficial as scientists and doctors can make better assessments about the treatment options and the patients receive personalized medicine with a better response rate. 

In cancer, CDx assays have tripled the rate of FDA approvals of new drug applications. We are developing tools CDx of solid tumors, COVID-19, and other areas that require personalized medicine.

Our tools help to increase the translational value of drug development. FlowCell’s approach focuses on biomarker development that provides a functional bridge between pre-clinical research and clinical trials.

For pre-clinical research, we supply tools that increase the relevance of the biological models such as organoids grown in the micro-physiological systems. Our specialty is microfluidics, a gatekeeper technique that works with single cells, tiny liquids, and other miniaturized biological systems. We have partnered with several suppliers of innovative tools in this field.

Our next stage of development includes hardware for measuring biomarkers in clinical settings (e.g. hospitals). This equipment will cut the size and cost of incumbent technologies tenfold and be capable of measuring cells, proteins, small molecules, electrolytes, and gasses.

Precision medicine requires precision data. Our innovative tools will enable the development of biomarkers during early research and translation in human trials. We call the entire process called bio-computation. Once data of sufficient quantity and precision is available, the problem shifts to bioinformatics. Without these innovative hardware tools, precision medicine will simply be AI processing an amount of data that are inadequate to the medical needs.